We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Maternal HbA1c Influences Autism Risk in Offspring

By LabMedica International staff writers
Posted on 04 Jul 2019
Epidemiologic data suggest that maternal diabetes influences the risk for autism in offspring, whereas the prevalence of autism has steadily risen in the USA, currently affecting 1 in 59 children, and boys are four to five times more likely to receive an autism diagnosis.

According to a comprehensive survey children born to women with glycated hemoglobin (HbA1c) level of at least 6.5% were nearly twice as likely to receive a diagnosis of autism in the first four years of life versus offspring of mothers with HbA1c below 5.7%.

Scientists carried out a retrospective study and analyzed electronic medical records data from 35,819 mother-infant pairs (51% boys) born in hospitals connected to Kaiser Permanente Southern California (Pasadena, CA, USA) from 2012 to 2013 (maternal mean maternal age, 31 years; mean pre-pregnancy BMI, 27.2 kg/m²; 51% Hispanic). More...
The team followed the children until they received a diagnosis of autism with at least one diagnostic code or December 31, 2017. The last maternal HbA1c level in the first two trimesters of pregnancy was obtained from the electronic laboratory database. HbA1c was analyzed as a continuous variable and a categorical variable, classified as less than 5.7%, 5.7% to 5.9%, 6% to 6.5%, and greater than 6.5%.

Within the cohort, 84.9% of mothers had an HbA1c less than 5.7%; 11.7% had an HbA1c between 5.7% and 5.9; 2.4% between 6% and 6.5%; and 1% greater than 6.5%. During a median follow-up of 4.5 years, 707 children (2%) had a clinical diagnosis of autism. After adjusting for pre-pregnancy BMI and race, the Hazard Ratio (HR) for autism associated with each 1% increase of HbA1c level was 1.12 (95% CI, 0.96-1.31) for the continuous measure. Compared with children with a maternal HbA1c of less than 5.7%, children born to women with an HbA1c greater than 6.5% were nearly twice as likely to receive a diagnosis of autism during follow-up (HR = 1.79; 95% CI, 1.06-3).

Anny H. Xiang, PhD, director of biostatistics for Kaiser Permanente Southern California, said, “Maternal diabetes, if not well treated, which means hyperglycemia in utero, that increases uterine inflammation, oxidative stress and hypoxia and may alter gene expression. This can disrupt fetal brain development, increasing the risk for neural behavior disorders, such as autism.” The study was presented at the American Diabetes Association 79th Scientific Meeting held June 7-11, 2019, in San Francisco, CA, USA.

Related Links:
Kaiser Permanente Southern California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.